Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Eli Lilly & Co. (LLY) shares have come under significant pressure in late May following a pivotal decision by CVS Health's ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) ...

To raise awareness about obesity and type 2 diabetes, Eli Lilly and Company (India) today announced partnership with Apollo Clinic, a prominent clinic network under Apollo Health and Lifestyle (AHLL) ...

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

Eli Lilly and Company (India) partners with Apollo Group to enhance awareness and healthcare solutions for obesity and type 2 ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Eli Lilly and Company (India) on Thursday said it has inked a pact with Apollo Group to raise awareness about obesity and type 2 diabetes. The company has ...

The initiative is planned to roll out across more than 200 Apollo clinics and involve 300 medical practitioners ...